

ASX ANNOUNCEMENT MARKET RELEASE

27 July 2022

Updated Appendix 4C for Q4 FY22

Artrya Limited (ASX: AYA), ("Artrya" or the "Company"), a medical technology company focused on commercialising its patented artificial intelligence platform, advises that there was an error on page 1 of the Appendix 4C Cash Flow Report for the quarter ended 30 June 2022 (**Appendix 4C**). On page 1 of the Appendix 4C, some of the year to date individual items for cash flows from operating activities were not correct and have now been corrected, however the net cash from / (used in) operating activities total for the current quarter and year to date (12 Months) have not changed. There are no other changes to the Appendix 4C. An updated Appendix 4C is now attached.

This announcement was approved by the Company's Managing Director, John Barrington, on behalf of the Artrya Board.

For further information please contact

Investor Enquiries:
John Barrington
Artrya Limited
+61 419 850 502
investors@artrya.com

Media Enquiries:
Brett McCarthy
Artrya Limited
+61 401 704 451
brett.mccarthy@artrya.com

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 and commenced operations in early 2019. Artrya Ltd is listed on the Australian Securities Exchange (ASX: AYA).

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of a patient at risk. The company has developed deep learning algorithms that will allow for the prediction and prevention of acute coronary events.

For more information, see www.artrya.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Artrya Limited

ABN

53 624 005 741

Quarter ended ("current quarter")

30 June 2022

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(1,110)	(2,589)
(b) product manufacturing and operating costs	(562)	(2,746)
(c) advertising and marketing	(397)	(2,099)
(d) leased assets	(78)	(85)
(e) staff costs	(1,696)	(5,023)
(f) administration and corporate costs	(371)	(1,507)
1.3 Dividends received (see note 3)		-
1.4 Interest received	20	30
1.5 Interest and other costs of finance paid	(13)	(13)
1.6 Income taxes paid		-
1.7 Government grants and tax incentives	15	992
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(4,192)	(13,040)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(1,007)	(1,906)
(d) investments **	9,000	(20,000)
(e) intellectual property	(75)	(243)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	4	4
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	7,922	(22,145)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	40,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	10
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(3,023)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (rental incentives)	898	898
3.10	Net cash from / (used in) financing activities	898	37,885

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	10,925	12,853
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,192)	(13,106)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	7,922	(22,145)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	898	37,885
4.5	Effect of movement in exchange rates on cash held	5	5
4.6	Cash and cash equivalents at end of period **	15,558	15,558

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances **	15,558	10,925
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	15,558	10,925

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	279
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

**** Note: Cash and cash equivalents**

Estimated cash available for future operating activities does not include term deposit funds of \$20m, which have been excluded from cash and cash equivalents in accordance with para. 7 of AASB 107 Statement of Cash Flows. If these term deposits were so included, item 8.4 total available funding would be \$35.6m and item 8.5 estimated quarters of funding available would equal to 8.53 quarters.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **27 July 2022**

Authorised by: **Board of Directors, Artrya Limited**

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.